Epoetin zeta
As of the edition of 20 October 2026, Epoetin zeta is a protein: marketed; acts on EPOR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Protein
- Brand name
- Retacrit
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Pfizer
- Registered trials
- 1, 0 stopped early
- Disease areas
- Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EPOR | Erythropoietin receptor | P19235 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 1 |